CLDN4 and ovarian carcinoma: CLDN3 and CLDN4 also regulate cisplatin sensitivity in ovarian cancer cells via copper transporter (CTR1), while CLDN7 enhances cisplatin sensitivity in lung cancer cells via the caspase pathway [183].